Emerging Company In An Emerging Market: CrownBio Transforms From CRO To Biotech
This article was originally published in PharmAsia News
Executive Summary
In a golden age of biotech in China, Crown is transforming from a biologics development service company to a mixed biotech through a planned IPO in Taiwan. Backed by its world-largest patient-derived xenograft models bank, the company is discovering oncology compounds.